{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:37:43Z","timestamp":1784810263100,"version":"3.55.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"25","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,18]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The transcription factor MECOM, located at 3q26, is essential for hematopoietic stem cells in healthy individuals. Enhancer translocations, due to 3q26 rearrangements, drive out-of-context MECOM expression in one of the most aggressive subtypes of acute myeloid leukemia (AML). Aberrantly expressed MECOM is essential for the survival and immature phenotype of these leukemia cells. Direct depletion of MECOM using an endogenous auxin-inducible degron immediately upregulates expression of CEBPA, which encodes a transcription factor required for neutrophil development and is frequently mutated in other AML subtypes. MECOM depletion is accompanied by a severe loss of CD34 and gain of mature myeloid cell surface marker CD15. MECOM exerts its inhibitory effect on differentiation by binding to the +42-kilobase CEBPA enhancer. This is partially dependent on the interaction between MECOM and its corepressor CTBP2. We demonstrate that CEBPA overexpression can bypass the MECOM-mediated block of differentiation. In addition, patients with AML with MECOM overexpression through enhancer hijacking show significantly reduced CEBPA levels. Our study directly connects 2 major players in normal and malignant hematopoiesis, MECOM and CEBPA, and unveils how MECOM maintains self-renewal by repressing CEBPA-induced differentiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025028914","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:53:43Z","timestamp":1759935223000},"page":"3098-3105","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["MECOM is a master repressor of myeloid differentiation through dose control of\n                    <i>CEBPA<\/i>\n                    in acute myeloid leukemia"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5322-1961","authenticated-orcid":false,"given":"Dorien","family":"Pastoors","sequence":"first","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"},{"name":"2Oncode Institute, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Havermans","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"},{"name":"2Oncode Institute, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0298-7948","authenticated-orcid":false,"given":"Roger","family":"Mulet-Lazaro","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"},{"name":"2Oncode Institute, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-8515","authenticated-orcid":false,"given":"Leonie","family":"Smeenk","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"},{"name":"2Oncode Institute, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ottema","sequence":"additional","affiliation":[{"name":"3Department of Clinical Genetics, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-4488","authenticated-orcid":false,"given":"Claudia","family":"Erpelinck-Verschueren","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"},{"name":"2Oncode Institute, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"van Herk","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"},{"name":"2Oncode Institute, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maikel","family":"Anthonissen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"},{"name":"2Oncode Institute, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-4603","authenticated-orcid":false,"given":"Tim","family":"Grob","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Subramanian","sequence":"additional","affiliation":[{"name":"4School of Clinical Medicine, University of New South Wales, Sydney, Australia"},{"name":"5Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-7230","authenticated-orcid":false,"given":"Julie A. I.","family":"Thoms","sequence":"additional","affiliation":[{"name":"6School of Biomedical Sciences, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-8962","authenticated-orcid":false,"given":"John E.","family":"Pimanda","sequence":"additional","affiliation":[{"name":"6School of Biomedical Sciences, University of New South Wales, Sydney, Australia"},{"name":"7Department of Clinical Haematology, Prince of Wales Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas J.","family":"Wouters","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2280-7617","authenticated-orcid":false,"given":"Berna","family":"Beverloo","sequence":"additional","affiliation":[{"name":"3Department of Clinical Genetics, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[{"name":"8Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[{"name":"8Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Zuber","sequence":"additional","affiliation":[{"name":"9Research Institute of Molecular Pathology, Vienna BioCenter, Vienna, Austria"},{"name":"10Medical University of Vienna, Vienna BioCenter, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bindels","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud","family":"Delwel","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"},{"name":"2Oncode Institute, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2025121811213687600_bib1","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/sj.emboj.7600679","article-title":"Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression","volume":"24","author":"Yuasa","year":"2005","journal-title":"EMBO J"},{"issue":"9","key":"2025121811213687600_bib2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/jmedgenet-2012-100990","article-title":"Deletion of the 3q26 region including the EVI1 and MDS1 genes in a neonate with congenital thrombocytopenia and subsequent aplastic anaemia","volume":"49","author":"Nielsen","year":"2012","journal-title":"J Med Genet"},{"issue":"2","key":"2025121811213687600_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.2019003701","article-title":"Atypical 3q26\/MECOM rearrangements genocopy inv(3)\/t(3;3) in acute myeloid leukemia","volume":"136","author":"Ottema","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2025121811213687600_bib4","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1182\/blood-2007-10-119230","article-title":"High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated","volume":"111","author":"Lugthart","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2025121811213687600_bib5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2002-05-1459","article-title":"High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients","volume":"101","author":"Barjesteh van Waalwijk van Doorn-Khosrovani","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2025121811213687600_bib6","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2009.26.0646","article-title":"High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities","volume":"28","author":"Gr\u00f6schel","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025121811213687600_bib7","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","article-title":"Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia","volume":"28","author":"Lugthart","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025121811213687600_bib8","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1073\/pnas.89.9.3937","article-title":"Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26","volume":"89","author":"Morishita","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2025121811213687600_bib9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","article-title":"A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia","volume":"157","author":"Gr\u00f6schel","year":"2014","journal-title":"Cell"},{"issue":"4","key":"2025121811213687600_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","article-title":"A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression","volume":"25","author":"Yamazaki","year":"2014","journal-title":"Cancer Cell"},{"issue":"11","key":"2025121811213687600_bib11","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/2159-8290.CD-20-1793","article-title":"Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer in leukemia","volume":"11","author":"Smeenk","year":"2021","journal-title":"Cancer Discov"},{"issue":"20","key":"2025121811213687600_bib12","doi-asserted-by":"crossref","first-page":"eadk9076","DOI":"10.1126\/sciadv.adk9076","article-title":"Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2","volume":"10","author":"Pastoors","year":"2024","journal-title":"Sci Adv"},{"issue":"8","key":"2025121811213687600_bib13","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/sj.bjc.6605874","article-title":"EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2","volume":"103","author":"G\u00f3mez-Benito","year":"2010","journal-title":"Br J Cancer"},{"issue":"1","key":"2025121811213687600_bib14","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1038\/s41467-018-06208-y","article-title":"EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription","volume":"9","author":"Ayoub","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"2025121811213687600_bib15","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1111\/cas.15098","article-title":"Evi1 upregulates Fbp1 and supports progression of acute myeloid leukemia through pentose phosphate pathway activation","volume":"112","author":"Mizuno","year":"2021","journal-title":"Cancer Sci"},{"issue":"5","key":"2025121811213687600_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood.2022016592","article-title":"EVI1 drives leukemogenesis through aberrant ERG activation","volume":"141","author":"Schmoellerl","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2025121811213687600_bib17","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3324\/haematol.2021.276048","article-title":"The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements","volume":"107","author":"Grasedieck","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2025121811213687600_bib18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12185-022-03465-y","article-title":"EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells","volume":"117","author":"Vinothkumar","year":"2023","journal-title":"Int J Hematol"},{"issue":"3","key":"2025121811213687600_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2141.2011.08737.x","article-title":"EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells","volume":"154","author":"De Weer","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"2025121811213687600_bib20","doi-asserted-by":"crossref","first-page":"e67134","DOI":"10.1371\/journal.pone.0067134","article-title":"Global identification of EVI1 target genes in acute myeloid leukemia","volume":"8","author":"Glass","year":"2013","journal-title":"PLoS One"},{"issue":"21","key":"2025121811213687600_bib21","doi-asserted-by":"crossref","first-page":"9783","DOI":"10.1073\/pnas.1004297107","article-title":"Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome","volume":"107","author":"Dickstein","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2025121811213687600_bib22","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1158\/0008-5472.CAN-06-3962","article-title":"Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis","volume":"67","author":"Senyuk","year":"2007","journal-title":"Cancer Res"},{"issue":"13","key":"2025121811213687600_bib23","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1182\/blood-2009-12-261602","article-title":"Evi1 represses PTEN expression and activates PI3K\/AKT\/mTOR via interactions with polycomb proteins","volume":"117","author":"Yoshimi","year":"2011","journal-title":"Blood"},{"issue":"26","key":"2025121811213687600_bib24","doi-asserted-by":"crossref","first-page":"13591","DOI":"10.1074\/jbc.M115.708156","article-title":"EVI1 interferes with myeloid maturation via transcriptional repression of Cebpa, via binding to two far downstream regulatory elements","volume":"291","author":"Wilson","year":"2016","journal-title":"J Biol Chem"},{"issue":"24","key":"2025121811213687600_bib25","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2016-01-695759","article-title":"An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation","volume":"127","author":"Avellino","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2025121811213687600_bib26","doi-asserted-by":"crossref","first-page":"e0150809","DOI":"10.1371\/journal.pone.0150809","article-title":"In vivo deletion of the Cebpa +37 kb enhancer markedly reduces Cebpa mRNA in myeloid progenitors but not in non-hematopoietic tissues to impair granulopoiesis","volume":"11","author":"Guo","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"2025121811213687600_bib27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nmeth.1401","article-title":"An auxin-based degron system for the rapid depletion of proteins in nonplant cells","volume":"6","author":"Nishimura","year":"2009","journal-title":"Nat Methods"},{"issue":"52","key":"2025121811213687600_bib28","doi-asserted-by":"crossref","first-page":"52651","DOI":"10.1074\/jbc.M307077200","article-title":"Restoration of C\/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation","volume":"278","author":"Tavor","year":"2003","journal-title":"J Biol Chem"},{"issue":"12","key":"2025121811213687600_bib29","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nmeth.4435","article-title":"Thiol-linked alkylation of RNA to assess expression dynamics","volume":"14","author":"Herzog","year":"2017","journal-title":"Nat Methods"},{"issue":"5","key":"2025121811213687600_bib30","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/bloodadvances.2021005851","article-title":"Induced cell-autonomous neutropenia systemically perturbs hematopoiesis in Cebpa enhancer-null mice","volume":"6","author":"Avellino","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2025121811213687600_bib31","doi-asserted-by":"crossref","first-page":"e0126385","DOI":"10.1371\/journal.pone.0126385","article-title":"The +37 kb Cebpa enhancer is critical for Cebpa myeloid gene expression and contains functional sites that bind SCL, GATA2, C\/EBPalpha, PU.1, and additional Ets factors","volume":"10","author":"Cooper","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"2025121811213687600_bib32","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.celrep.2017.05.005","article-title":"RUNX1-ETO and RUNX1-EVI1 differentially reprogram the chromatin landscape in t(8;21) and t(3;21) AML","volume":"19","author":"Loke","year":"2017","journal-title":"Cell Rep"},{"issue":"3","key":"2025121811213687600_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/bloodadvances.2017012781","article-title":"C\/EBP\u03b1 overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemia","volume":"2","author":"Loke","year":"2018","journal-title":"Blood Adv"},{"issue":"21","key":"2025121811213687600_bib34","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.2020007747","article-title":"RUNX1 and CBF\u03b2-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development","volume":"136","author":"Zhen","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2025121811213687600_bib36","first-page":"3019","article-title":"CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias","volume":"146","author":"Fleming","year":"2025","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/25\/3098\/2476624\/blood_bld-2025-028914-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/25\/3098\/2476624\/blood_bld-2025-028914-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:21:48Z","timestamp":1766074908000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/25\/3098\/547639\/MECOM-is-a-master-repressor-of-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":35,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2025,12,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025028914","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,18]]},"published":{"date-parts":[[2025,12,18]]}}}